CBLLCeribell, Inc.
Electromedical & Electrotherapeutic Apparatus
- Revenue
- $89M
- 36% YoY
- Operating margin
- -65.6%
- 8.1% YoY
- EBITDA
- −$57M
- 48% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired14% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $45M | $65M | $89M | 36% |
| Operating income | −$30M | −$40M | −$58M | 47% |
| Net income | −$29M | −$40M | −$53M | 32% |
| Operating cash flow | −$29M | −$35M | −$41M | 16% |
| Capex | $983K | $1M | $767K | 43% |
| Stock-based comp | $3M | $5M | $12M | 126% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 10
- Net
- −$2M
Pay vs performance
No pay-versus-performance disclosure yet.